Sale!

KCNQ1 Gene Short QT Syndrome Type 2 Genetic Test Cost

Original price was: 5,600 د.إ.Current price is: 4,400 د.إ.

-21%

The KCNQ1 Gene Short QT Syndrome Type 2 Genetic Test is a specialized diagnostic tool offered by DNA Labs UAE, designed to detect mutations in the KCNQ1 gene that are associated with Short QT Syndrome Type 2 (SQTS2). This condition is a rare form of heart rhythm disorder characterized by a shortened QT interval on the electrocardiogram (ECG), which can increase the risk of sudden cardiac death due to arrhythmias. The test is crucial for individuals with a family history of SQTS or unexplained cardiac events, as it helps in the early identification and management of the condition. Conducted through a blood sample, the genetic analysis provides comprehensive insights into the KCNQ1 gene, enabling personalized treatment plans and preventive measures for affected individuals and their families. The cost of the test is 4400 AED, reflecting the advanced technology and expertise involved in the genetic analysis at DNA Labs UAE.

Home  Sample collection service available

  • 100% accuaret Test Results
  • Ranked as Most trusted Genetic DNA Lab
  • This test is not intended for medical diagnosis or treatment
Guaranteed Safe Checkout

KCNQ1 Gene Short QT syndrome type 2 Genetic Test

Welcome to DNA Labs UAE, where we offer the KCNQ1 Gene Short QT syndrome type 2 Genetic Test. This test helps in diagnosing and understanding the risk of Short QT syndrome type 2, a condition characterized by a shortened QT interval on an electrocardiogram (ECG) and an increased risk of life-threatening arrhythmias.

Test Components

  • Price: 4400.0 AED
  • Sample Condition: Blood or Extracted DNA or One drop Blood on FTA Card
  • Report Delivery: 3 to 4 Weeks
  • Method: NGS Technology
  • Test Type: Cardiovascular Pneumology Disorders
  • Doctor: Cardiologist
  • Test Department: Genetics

Pre Test Information

Prior to undergoing the KCNQ1 Gene Short QT syndrome type 2 NGS Genetic DNA Test, it is important to provide the clinical history of the patient. Additionally, a genetic counseling session will be conducted to draw a pedigree chart of family members affected by KCNQ1 Gene Short QT syndrome type 2.

Test Details

The KCNQ1 gene is responsible for encoding a protein that helps regulate the electrical activity of the heart. Mutations in this gene can lead to Short QT syndrome type 2. To analyze the KCNQ1 gene for potential mutations or variants associated with the condition, we utilize NGS (Next-Generation Sequencing) technology. NGS allows for the simultaneous sequencing of multiple genes or even the entire genome.

The KCNQ1 gene mutations in Short QT syndrome type 2 NGS Genetic DNA Test involve obtaining a DNA sample, typically through a blood sample or cheek swab. The DNA is then sequenced using NGS technology. The resulting sequence data is analyzed to identify any mutations or variants in the KCNQ1 gene that may contribute to the individual’s risk of developing Short QT syndrome type 2.

This genetic test can help confirm a diagnosis of Short QT syndrome type 2 in individuals with clinical symptoms or a family history of the condition. It also aids in genetic counseling and treatment decisions, such as the use of medications or implantable devices to manage the risk of arrhythmias.

Test Name KCNQ1 Gene Short QT syndrome type 2 Genetic Test
Components
Price 4400.0 AED
Sample Condition Blood or Extracted DNA or One drop Blood on FTA Card
Report Delivery 3 to 4 Weeks
Method NGS Technology
Test type Cardiovascular Pneumology Disorders
Doctor Cardiologist
Test Department: Genetics
Pre Test Information Clinical History of Patient who is going for KCNQ1 Gene Short QT syndrome type 2 NGS Genetic DNA Test. A Genetic Counselling session to draw a pedigree chart of family members affected with KCNQ1 Gene Short QT syndrome type 2 NGS Genetic DNA Test gene KCNQ1
Test Details

The KCNQ1 gene is responsible for encoding a protein that helps regulate the electrical activity of the heart. Mutations in this gene can lead to a condition called Short QT syndrome type 2, which is characterized by a shortened QT interval on an electrocardiogram (ECG) and an increased risk of life-threatening arrhythmias.

NGS (Next-Generation Sequencing) is a high-throughput sequencing technology that allows for the simultaneous sequencing of multiple genes or even the entire genome. In the context of genetic testing for Short QT syndrome type 2, NGS can be used to analyze the KCNQ1 gene for any potential mutations or variants that may be associated with the condition.

The NGS genetic test for KCNQ1 gene mutations in Short QT syndrome type 2 involves obtaining a DNA sample, usually through a blood sample or cheek swab, and then sequencing the DNA using NGS technology. The resulting sequence data is then analyzed to identify any mutations or variants in the KCNQ1 gene that may be contributing to the individual’s risk of developing Short QT syndrome type 2.

This genetic test can help confirm a diagnosis of Short QT syndrome type 2 in individuals with clinical symptoms or a family history of the condition. It can also be used for genetic counseling and to inform treatment decisions, such as the use of medications or implantable devices to manage the risk of arrhythmias.